PCSK9 and COVID-19: In this way, both statins and PCSK9 inhibitors are valuable adjuncts to the overall antithrombotic armamentarium in hospitalized hypercholesterolemic COVID-19 patients, particularly in COVID-19 patients with severe hypercholesterolemia—whether or not they have the diagnosis of HeFH.